Obsidian Therapeutics Announces Closing of $115 Million Series B Financing

Funding to Advance Pipeline of Engineered TIL Therapies for Solid Tumors into Clinical Studies Existing investors Atlas Venture, Vertex Ventures HC, Amgen Ventures, and Bristol Myers Squibb participated in the financing.Also participating in the round is Vertex Pharmaceuticals, with whom Obsidian recently executed a collaboration to discover novel therapies that regulate gene editing.

Continue Reading Obsidian Therapeutics Announces Closing of $115 Million Series B Financing

Evommune Inc., Completes $83 Million Series A Financing to Advance Development of Unique Chronic Inflammation Pipeline

The financing enables Evommune to continue the research and development of transformative therapies through both industry and academic collaborations to treat patients with immune-mediated and chronic inflammatory diseases. This financing will allow us to advance all four of the programs in our pipeline into the clinic."

Continue Reading Evommune Inc., Completes $83 Million Series A Financing to Advance Development of Unique Chronic Inflammation Pipeline